表达猪轮状病毒VP4基因和共表达VP4与LTB重组乳酸菌表达系统的构建及其免疫学评价
|
摘要
猪轮状病毒是无囊膜、分节段的双股RNA病毒,隶属于呼肠孤病毒科,是引起仔猪腹泻的重要病原之一。猪轮状病毒感染呈世界范围分布,给养猪业带来了极大的危害。
本研究以乳酸乳球菌Lactococcus lactis NZ9000和干酪乳杆菌Lactobacillus casei ATCC 393(L.casei 393)作为递呈抗原的活菌载体,以猪轮状病毒主要免疫保护性抗原VP4蛋白的基因片段为靶基因,并插入大肠杆菌不耐热肠毒素B亚基因(LTB),构建了表达猪轮状病毒VP4基因和共表达VP4-LTB的重组乳酸乳球菌表达系统和干酪乳杆菌表达系统,并对免疫效果进行比较分析。
根据目的基因和融合表达载体质粒的特点,应用oligo6.0软件进行设计引物。以VP4-pGEX-6P-1质粒作为模板,通过PCR扩增得到大约756 bp的VP4基因,以pMD-18T-LTB质粒作为模板,通过PCR扩增得到大约375 bp的LTB基因,PCR产物经酶切后,与带有粘性末端的pNZ8112载体连接,得到pNZ8112-VP4和pNZ8112-VP4-LTB的质粒。重组质粒pNZ8112-VP4和pNZ8112-VP4-LTB分别电转化乳酸乳球菌NZ9000 ,得到重组菌pNZ8112-VP4和pNZ8112-VP4-LTB,然后将重组菌进行酶切、PCR鉴定和测序分析。以同样方法得到pPG-1-VP4和pPG-1-VP4-LTB重组菌,然后进行酶切、PCR鉴定和测序分析。
构建的重组菌pNZ8112-VP4和pNZ8112-VP4-LTB在GM17培养液中培养,通过Nisin来诱导目的蛋白的表达。重组菌中蛋白的表达和定位通过SDS-PAGE、Western blotting和免疫荧光进行鉴定。考马斯亮蓝染色结果显示:pNZ8112-VP4和pNZ8112-VP4-LTB的菌体裂解物分别表达了27KD和40KD的融合蛋白,而诱导前的菌体没有目的蛋白表达。诱导后表达的VP4和VP4-LTB蛋白经Western blotting分析,可检测到27KD和40KD的特异性反应条带,诱导前的菌体没有相应的条带出现。这些结果表明Nisin能有效诱导乳酸乳球菌NZ9000中异源蛋白的表达。采用抗VP4的鼠血清进行免疫荧光试验的结果显示,pNZ8112-VP4和pNZ8112-VP4-LTB诱导后的菌体表面能看到黄绿色荧光,而诱导前的菌体则没有荧光反应,且细胞被伊文思蓝染成红色。
构建的重组菌pPG-1-VP4和pPG-1-VP4-LTB在MRS培养液中进行培养,利用乳糖来诱导目的蛋白的表达。重组菌目的蛋白的表达和定位也是通过SDS-PAGE、Western blotting和免疫荧光来鉴定。考马斯亮蓝染色可看到pPG-1-VP4和pPG-1-VP4-LTB的菌体裂解物分别有大约40KD和53KD的蛋白表达,而未诱导的菌体中没有蛋白表达。通过Western blotting检测诱导后的菌体裂解物,可看到40KD和53KD的特异性反应条带,而未诱导的菌体则没有相应的条带出现,这些结果表明乳糖能有效诱导L.casei 393中异源蛋白的表达。通过间接免疫荧光方法鉴定,pPG-1-VP4和pPG-1-VP4-LTB的菌体表面均能看到黄绿色荧光,而未诱导的菌体则没有荧光反应,且细胞被伊文思蓝染成红色。
为检验重组菌是否能诱导黏膜和系统免疫应答,将BALB/c小鼠分为六组,通过口服途径分别免疫pPG-1 , pPG-1-VP4 , pPG-1-VP4-LTB , pNZ8112 , pNZ8112-VP4和pNZ8112-VP4-LTB。每只小鼠分别免疫109 c.f.u.单位的重组菌,每次连续免疫三天,第一次加强免疫在第一次免疫后的17、18、19天,第二次加强免疫在第一次免疫后的33、34、35天。每次免疫后的第7天收集小鼠血清;每次免疫后的1、2、7天收集粪便;眼洗液是在每次免疫后的第7天以50μL的PBS冲洗眼结膜获得;阴道洗液是在每次免疫后的第7天用200μL的PBS冲洗阴道获得;母鼠分娩后的3、5、7天收集乳汁。所有收集的样品保存于–20℃备用。
为保持黏膜系统的稳定,许多防御机制都参与进行持久有效地作用。分泌性IgA的参与也是防御机制之一,IgA抗体通过阻止病原微生物的入侵和定植并竞争受体和代谢底物。为评价黏膜免疫反应,通过ELISA方法来检测黏膜样品中特异性IgA抗体的水平。在粪便、眼洗液和阴道洗液中我们检测到了高水平的特异性IgA,与对照组相比差异显著。其中免疫pPG-1-VP4的小鼠中特异性IgA抗体水平高于免疫pNZ8112-VP4的小鼠,免疫pPG-1-VP4-LTB的小鼠中特异性IgA抗体水平也高于免疫pNZ8112-VP4-LTB的小鼠,这是因为L.casei 393同Lactococcus lactis NZ9000相比具有更好的肠道定植能力。免疫pPG-1-VP4-LTB和pNZ8112-VP4-LTB的小鼠粪便、眼洗液和阴道样品中IgA抗体水平均高于免疫pPG-1-VP4和pNZ8112-VP4的小鼠。这是由于添加了黏膜免疫佐剂LTB的缘故,表明LTB能加强黏膜系统反应。具有低免疫原性的疫苗尤其需要强有力的佐剂来加强抗原递呈,本研究证明LTB作为一种安全有效的佐剂具有极大的潜力。
免疫pPG-1-VP4和pPG-1-VP4-LTB的小鼠血清中IgG的效价相当,但都高于免疫pPG-1的对照组。免疫pNZ8112-VP4和pNZ8112-VP4-LTB的小鼠血清中IgG抗体的效价相当,但都高于免疫pNZ8112的对照组。在本研究中,口服免疫表达VP4和VP4-LTB的重组乳酸菌不仅能诱导产生黏膜免疫,而且诱导产生了系统免疫。通过口服免疫产生的黏膜免疫反应不只局限于胃肠道,也引起了其他黏膜部位的免疫反应。IgA抗体能和抗原结合并阻止其进入,降低炎性反应的程度,从而阻止了对组织的损伤,通过分泌性IgA抗体在黏膜表面对病原体进行排斥和清除,这对预防轮状病毒感染是至关重要的。
将新分离的免疫鼠脾细胞稀释成5×106个/ mL并培养66h,分别用0.5μg/mL,5μg/mL和25μg/mL的VP4抗原进行刺激,收获培养上清用于检测细胞因子。脾淋巴细胞的增殖通过ELISA进行检测,结果表明0.5μg/mL和5μg/mL的VP4与25μg/mL的VP4相比,具有更强的刺激增殖作用。IL-4和IFN-γ的检测采用Biosource检测试剂盒,方法参照说明书。结果表明免疫组中IL-4和IFN-γ的分泌显著高于对照组,组间差异显著,且分泌IL-4的水平显著高于IFN-γ。这些数据表明,通过口服途径免疫重组菌后引起了显著的细胞因子反应,从而加强了抵抗轮状病毒感染的保护作用。
免疫母鼠产仔后的3、5、7天收集乳汁,通过ELISA方法检测乳汁中的特异性抗体,结果显示乳汁样品中有较高水平的特异性IgA,表明免疫重组菌产生的抗体对于幼龄动物的被动免疫保护有一定作用。
综上所述,本研究所获得的结果表明,乳酸乳球菌和干酪乳杆菌可用做口服免疫传递抗原引起黏膜和系统免疫。乳酸菌作为疫苗传递载体能够定植于不同的黏膜部位,例如胃肠道、生殖道等,可被用于接种在病原体入侵的部位来抵抗感染。乳酸菌安全无毒的特点使它们更适合于用做口服疫苗载体来传递异源抗原,重组乳酸菌具有较好的免疫原性,并能引起较好的黏膜免疫反应和系统免疫反应。当VP4蛋白与LTB共表达时,加强了黏膜免疫反应,LTB具有较好的免疫原性、抗原性和佐剂特性,可被用于基因工程疫苗的研制,很适合于用做黏膜疫苗的免疫佐剂。本研究为进一步研究新型、有效的猪轮状病毒口服疫苗奠定了基础。
Porcine rotaviruses are nonenveloped, segmented, doublestranded RNA viruses classified in the family Reoviridae. Porcine rotaviruses are the major cause of diarrhea in the piglets .Porcine rotavirus has been widely distributed in the world and cost pig producers serious loss.
In this study, Lactococcus lactis NZ9000 and Lactobacillus casei ATCC 393 (L.casei 393) were selected as an antigen delivery vehicle for the development of live mucosal vaccine. The main protective antigen VP4 was selected as the target gene and E.coli heat-labile toxin B subunit protein was inserted. We constructed recombinant Lactococcus lactis NZ9000 and recombinant L.casei 393 systems expressing VP4 and co-expressing VP4-LTB.The immunogenicity responses induced by oral mucosal immunizations with recombinant strains were compared.
We designed primers with oligo6.0 software according with target gene and considering the characters of fusion expression vector plasmid. About 756bp gene fragment (VP4) and 375bp gene fragment were amplified by PCR using the plasmid VP4-pGEX-6P-1 and the plasmid pMD-18T-LTB. The PCR products were digested by restriction enzyme, linked with expression vector pNZ8112 digested by restriction enzyme , giving rise to pNZ8112-VP4 and pNZ8112-VP4-LTB.The recombinant plasmids pNZ8112-VP4 and pNZ8112-VP4-LTB were electroporated into Lactococcus lactis NZ9000 respectively, generating pNZ8112-VP4/ NZ9000 and pNZ8112-VP4-LTB/ NZ9000 followed enzyme digestion, PCR identification and sequence analysis.At the same time, we obtained pPG-1-VP4/ L.casei 393 and pPG-1-VP4-LTB/ L.casei 393 by the same way.They also followed enzyme digestion, PCR identification and sequence analysis.
The recombinant strains pNZ8112-VP4 and pNZ8112-VP4-LTB constructed were induced by Nisin in GM17 medium to express interest protein. The expression and localization of the protein from recombinant strains were detected via SDS-PAGE , Western blotting , and immunofluorescence. The lysates of the cells were analyzed by SDS-PAGE. Coomassie blue gel staining showed that 27KD and 40KD fusion protein were expressed in lysates of pNZ8112-VP4 and pNZ8112-VP4-LTB, but not expressed when the same cells were grown in GM17 medium without Nisin . The localization of the VP4 and VP4-LTB protein nisin-induced were analyzed via Western blotting .Immunoreactive bands (27KD,40KD) were detected , and corresponding immunoreactive bands did not display when they were not induced. These results show that Nisin promoter from Lactococcus lactis NZ9000 could efficiently induce the expression of heterologous protein. The immunofluorescence was developed with the mouse anti-VP4 serum. The results indicated that there was green-yellow fluorescence on the cell surface of pNZ8112-VP4 and pNZ8112-VP4-LTB when induced. The cells uninduced did not display an immunofluorescence reaction and were dyed red by Evans blue.
The recombinant strains pPG-1-VP4 and pPG-1-VP4-LTB constructed in this study were induced by lactose in MRS medium to express interest protein. The expression and localization of the protein from pPG-1-VP4 and pPG-1-VP4-LTB were also detected via SDS-PAGE, Western blotting, and immunofluorescence. The lysates of the cells were analyzed by SDS-PAGE. Coomassie blue gel staining showed that 40KD and 53KD fusion protein were expressed in lysates of pPG-1-VP4 and pPG-1-VP4-LTB, but not expressed when the same cells were grown in MRS medium without lactose . The localization of the VP4 and VP4-LTB protein lactose-induced were analyzed via Western blotting .Immunoreactive bands (40KD,53KD) were detected , and corresponding immunoreactive bands did not display when they were not induced. These results show that lactose promoter from L.casei 393 could efficiently induce the expression of heterologous protein. The immunofluorescence was developed with the mouse anti-VP4 serum. The results indicated that there was green-yellow fluorescence on the cell surface of pPG-1-VP4 and pPG-1-VP4-LTB when induced. The cells uninduced did not display an immunofluorescence reaction and were dyed red by Evans blue.
To identify whether the recombinant strains have the ability to induce systemic and mucosal antibody responses, six groups of ten female mice were immunized via oral route with pPG-1, pPG-1-VP4,pPG-1-VP4-LTB,pNZ8112,pNZ8112-VP4 and pNZ8112-VP4-LTB respectively. Every mouse received dose of 109 colony-forming units (c.f.u.)/mL of recombinant strains, respectively. The immune protocol was administered on three consecutive days at days 1,2 and 3. A booster immunization was given at days 17,18 and 19 and a second booster was given at days 33,34 and 35. Serum of mice were collected 7 days after every immunization. Fecal pellets were collected 1, 2, and 7 days after every immunization. Ophthalmic wash were obtained by washing the eyes with 50μL phosphate-buffered saline (PBS) 7 days after every immunization. Vaginal samples were collected by washing the vagina with 200μL PBS 7 days after every immunization . Milk were collected 3、5、7 days after delivery. All samples were stored at–20℃until required.
To maintain homeostasis in the mucosae,different defense mechanisms are involved in permanent and effective surveillance. One of these mechanisms is the secretory immune system through IgA antibodies. IgA prevents the invasion and colonization of pathogenic microorganisms and competes for receptors and metabolic substrates. To assess mucosal immune responses, specific IgA levels in mucosal samples were determined by ELISA. Specific IgA reached a high level in the fecal pellets,ophthalmic and vaginal wash. In contrast,only background levels of antibodies were detected in control animals.The IgA levels of mice administered with pPG-1-VP4 are higher than those administered with pNZ8112-VP4. The IgA levels of mice administered with pPG-1-VP4-LTB are higher than those administered with pNZ8112-VP4-LTB. This is because L.casei 393 has better colonization ability in intestinal tracts than Lactococcus lactis NZ9000. The IgA levels of mice administered with pPG-1-VP4-LTB or pNZ8112-VP4-LTB are higher than those administered with pPG-1-VP4 or pNZ8112-VP4 in fecal, ophthalmic and vaginal samples. This is due to the addition of mucosal immunoadjuvant LTB. This indicates that LTB can enhance the mucosal system response. Vaccines with low immunogenicity in particular require the use of a strong adjuvant to enhance the antigen-presenting .This study has highlighted the potential of LTB as a safe and effective adjuvant.
IgG titers of serum in mice given pPG-1-VP4 or pPG-1-VP4-LTB were similar but higher than the mice given pPG-1. IgG titers of serum in mice given pNZ8112-VP4 or pNZ8112-VP4-LTB were similar but higher than the mice given pNZ8112. In this study, oral administration of recombinant strains displaying VP4 or VP4-LTB protein antigens induced both systemic and mucosal immune responses. Oral immunization elicited specific mucosal responses at the site of gastrointestinal tract, as well as the remote mucosal sites. The IgA antibodies can bind the antigen and minimize its entry with a consequent reduction in inflammatory reactions, which prevents a potentially harmful effect on the tissue . The immune exclusion and elimination of the pathogen at the mucosal surfaces by secretory IgA is crucial in preventing porcine rotavirus .
Freshly isolated mouse splenocytes were seeded at 5×106 cells/mL and incubated for 66 h. 0.5μg/mL,5μg/mL and 25μg/mL VP4 were added to challenge.Cell culture supernatants were harvested and analyzed for the presence of cytokines. Splenic lymphocyte proliferation assay was measured by ELISA. The result indicated that 0.5μg/mL and 5μg/mL VP4 have stronger challenge than 25μg/mL VP4. Interleukin-4 (IL-4) and gamma interferon (IFN-γ) cytokine assays were performed using Biosource ELISA kits according to the manufacturer’s instructions. The result indicated that all immunized groups secreted significantly more IL-4 and IFN-γthan the control group.Significant differences were seen among the groups. Immunized mice secreted increased levels of IL-4 that were significantly higher than IFN-γ. Overall, these data show that immunization of recombinant strains via oral route produced significant innate-type cytokine responses. It suggested that enhanced protection against infection of rotavirus .
Furthermore, we collected the milk of mice 3、5、7 days after delivery.Specific IgA in the milk were detected by ELISA.The result indicated that there were high levels of specific IgA in the samples.It shows that antibodies produced by administration with recombinant strains can serve passive immunoprotection to the immature animals.
In conclusion , the results obtained so far demonstrate that Lactococcus lactis and lactobacillus are capable of delivering antigen to the mucosal and systemic immune systems following oral immunization. Lactic acid bacteria as vaccine delivery vehicles are able to colonize different mucosal sites such as gastrointestinal tracts, genital tracts and could thus be used specifically to vaccinate against pathogens at their site of entry. Their harmLess nature make them more appropriate as an oral vaccine carrier to deliver heterologous antigens. The recombinant strains have better immunogenicity and can elicit stronger specific mucosal immune responses and systematic immune responses. When VP4 was co-expressed with LTB, it showed much stronger mucosal immune responses. It indicated that LTB with qualified immunoreactivity, antigenicity and adjuvanticity could be used to develop genetically engineered vaccine. It should be suitably applicable as an immunoadjuvant for mucosal vaccines.All theses work established a good foundation for further study on the new and effective recombinant oral vaccine of porcine rotavirus.
本研究以乳酸乳球菌Lactococcus lactis NZ9000和干酪乳杆菌Lactobacillus casei ATCC 393(L.casei 393)作为递呈抗原的活菌载体,以猪轮状病毒主要免疫保护性抗原VP4蛋白的基因片段为靶基因,并插入大肠杆菌不耐热肠毒素B亚基因(LTB),构建了表达猪轮状病毒VP4基因和共表达VP4-LTB的重组乳酸乳球菌表达系统和干酪乳杆菌表达系统,并对免疫效果进行比较分析。
根据目的基因和融合表达载体质粒的特点,应用oligo6.0软件进行设计引物。以VP4-pGEX-6P-1质粒作为模板,通过PCR扩增得到大约756 bp的VP4基因,以pMD-18T-LTB质粒作为模板,通过PCR扩增得到大约375 bp的LTB基因,PCR产物经酶切后,与带有粘性末端的pNZ8112载体连接,得到pNZ8112-VP4和pNZ8112-VP4-LTB的质粒。重组质粒pNZ8112-VP4和pNZ8112-VP4-LTB分别电转化乳酸乳球菌NZ9000 ,得到重组菌pNZ8112-VP4和pNZ8112-VP4-LTB,然后将重组菌进行酶切、PCR鉴定和测序分析。以同样方法得到pPG-1-VP4和pPG-1-VP4-LTB重组菌,然后进行酶切、PCR鉴定和测序分析。
构建的重组菌pNZ8112-VP4和pNZ8112-VP4-LTB在GM17培养液中培养,通过Nisin来诱导目的蛋白的表达。重组菌中蛋白的表达和定位通过SDS-PAGE、Western blotting和免疫荧光进行鉴定。考马斯亮蓝染色结果显示:pNZ8112-VP4和pNZ8112-VP4-LTB的菌体裂解物分别表达了27KD和40KD的融合蛋白,而诱导前的菌体没有目的蛋白表达。诱导后表达的VP4和VP4-LTB蛋白经Western blotting分析,可检测到27KD和40KD的特异性反应条带,诱导前的菌体没有相应的条带出现。这些结果表明Nisin能有效诱导乳酸乳球菌NZ9000中异源蛋白的表达。采用抗VP4的鼠血清进行免疫荧光试验的结果显示,pNZ8112-VP4和pNZ8112-VP4-LTB诱导后的菌体表面能看到黄绿色荧光,而诱导前的菌体则没有荧光反应,且细胞被伊文思蓝染成红色。
构建的重组菌pPG-1-VP4和pPG-1-VP4-LTB在MRS培养液中进行培养,利用乳糖来诱导目的蛋白的表达。重组菌目的蛋白的表达和定位也是通过SDS-PAGE、Western blotting和免疫荧光来鉴定。考马斯亮蓝染色可看到pPG-1-VP4和pPG-1-VP4-LTB的菌体裂解物分别有大约40KD和53KD的蛋白表达,而未诱导的菌体中没有蛋白表达。通过Western blotting检测诱导后的菌体裂解物,可看到40KD和53KD的特异性反应条带,而未诱导的菌体则没有相应的条带出现,这些结果表明乳糖能有效诱导L.casei 393中异源蛋白的表达。通过间接免疫荧光方法鉴定,pPG-1-VP4和pPG-1-VP4-LTB的菌体表面均能看到黄绿色荧光,而未诱导的菌体则没有荧光反应,且细胞被伊文思蓝染成红色。
为检验重组菌是否能诱导黏膜和系统免疫应答,将BALB/c小鼠分为六组,通过口服途径分别免疫pPG-1 , pPG-1-VP4 , pPG-1-VP4-LTB , pNZ8112 , pNZ8112-VP4和pNZ8112-VP4-LTB。每只小鼠分别免疫109 c.f.u.单位的重组菌,每次连续免疫三天,第一次加强免疫在第一次免疫后的17、18、19天,第二次加强免疫在第一次免疫后的33、34、35天。每次免疫后的第7天收集小鼠血清;每次免疫后的1、2、7天收集粪便;眼洗液是在每次免疫后的第7天以50μL的PBS冲洗眼结膜获得;阴道洗液是在每次免疫后的第7天用200μL的PBS冲洗阴道获得;母鼠分娩后的3、5、7天收集乳汁。所有收集的样品保存于–20℃备用。
为保持黏膜系统的稳定,许多防御机制都参与进行持久有效地作用。分泌性IgA的参与也是防御机制之一,IgA抗体通过阻止病原微生物的入侵和定植并竞争受体和代谢底物。为评价黏膜免疫反应,通过ELISA方法来检测黏膜样品中特异性IgA抗体的水平。在粪便、眼洗液和阴道洗液中我们检测到了高水平的特异性IgA,与对照组相比差异显著。其中免疫pPG-1-VP4的小鼠中特异性IgA抗体水平高于免疫pNZ8112-VP4的小鼠,免疫pPG-1-VP4-LTB的小鼠中特异性IgA抗体水平也高于免疫pNZ8112-VP4-LTB的小鼠,这是因为L.casei 393同Lactococcus lactis NZ9000相比具有更好的肠道定植能力。免疫pPG-1-VP4-LTB和pNZ8112-VP4-LTB的小鼠粪便、眼洗液和阴道样品中IgA抗体水平均高于免疫pPG-1-VP4和pNZ8112-VP4的小鼠。这是由于添加了黏膜免疫佐剂LTB的缘故,表明LTB能加强黏膜系统反应。具有低免疫原性的疫苗尤其需要强有力的佐剂来加强抗原递呈,本研究证明LTB作为一种安全有效的佐剂具有极大的潜力。
免疫pPG-1-VP4和pPG-1-VP4-LTB的小鼠血清中IgG的效价相当,但都高于免疫pPG-1的对照组。免疫pNZ8112-VP4和pNZ8112-VP4-LTB的小鼠血清中IgG抗体的效价相当,但都高于免疫pNZ8112的对照组。在本研究中,口服免疫表达VP4和VP4-LTB的重组乳酸菌不仅能诱导产生黏膜免疫,而且诱导产生了系统免疫。通过口服免疫产生的黏膜免疫反应不只局限于胃肠道,也引起了其他黏膜部位的免疫反应。IgA抗体能和抗原结合并阻止其进入,降低炎性反应的程度,从而阻止了对组织的损伤,通过分泌性IgA抗体在黏膜表面对病原体进行排斥和清除,这对预防轮状病毒感染是至关重要的。
将新分离的免疫鼠脾细胞稀释成5×106个/ mL并培养66h,分别用0.5μg/mL,5μg/mL和25μg/mL的VP4抗原进行刺激,收获培养上清用于检测细胞因子。脾淋巴细胞的增殖通过ELISA进行检测,结果表明0.5μg/mL和5μg/mL的VP4与25μg/mL的VP4相比,具有更强的刺激增殖作用。IL-4和IFN-γ的检测采用Biosource检测试剂盒,方法参照说明书。结果表明免疫组中IL-4和IFN-γ的分泌显著高于对照组,组间差异显著,且分泌IL-4的水平显著高于IFN-γ。这些数据表明,通过口服途径免疫重组菌后引起了显著的细胞因子反应,从而加强了抵抗轮状病毒感染的保护作用。
免疫母鼠产仔后的3、5、7天收集乳汁,通过ELISA方法检测乳汁中的特异性抗体,结果显示乳汁样品中有较高水平的特异性IgA,表明免疫重组菌产生的抗体对于幼龄动物的被动免疫保护有一定作用。
综上所述,本研究所获得的结果表明,乳酸乳球菌和干酪乳杆菌可用做口服免疫传递抗原引起黏膜和系统免疫。乳酸菌作为疫苗传递载体能够定植于不同的黏膜部位,例如胃肠道、生殖道等,可被用于接种在病原体入侵的部位来抵抗感染。乳酸菌安全无毒的特点使它们更适合于用做口服疫苗载体来传递异源抗原,重组乳酸菌具有较好的免疫原性,并能引起较好的黏膜免疫反应和系统免疫反应。当VP4蛋白与LTB共表达时,加强了黏膜免疫反应,LTB具有较好的免疫原性、抗原性和佐剂特性,可被用于基因工程疫苗的研制,很适合于用做黏膜疫苗的免疫佐剂。本研究为进一步研究新型、有效的猪轮状病毒口服疫苗奠定了基础。
Porcine rotaviruses are nonenveloped, segmented, doublestranded RNA viruses classified in the family Reoviridae. Porcine rotaviruses are the major cause of diarrhea in the piglets .Porcine rotavirus has been widely distributed in the world and cost pig producers serious loss.
In this study, Lactococcus lactis NZ9000 and Lactobacillus casei ATCC 393 (L.casei 393) were selected as an antigen delivery vehicle for the development of live mucosal vaccine. The main protective antigen VP4 was selected as the target gene and E.coli heat-labile toxin B subunit protein was inserted. We constructed recombinant Lactococcus lactis NZ9000 and recombinant L.casei 393 systems expressing VP4 and co-expressing VP4-LTB.The immunogenicity responses induced by oral mucosal immunizations with recombinant strains were compared.
We designed primers with oligo6.0 software according with target gene and considering the characters of fusion expression vector plasmid. About 756bp gene fragment (VP4) and 375bp gene fragment were amplified by PCR using the plasmid VP4-pGEX-6P-1 and the plasmid pMD-18T-LTB. The PCR products were digested by restriction enzyme, linked with expression vector pNZ8112 digested by restriction enzyme , giving rise to pNZ8112-VP4 and pNZ8112-VP4-LTB.The recombinant plasmids pNZ8112-VP4 and pNZ8112-VP4-LTB were electroporated into Lactococcus lactis NZ9000 respectively, generating pNZ8112-VP4/ NZ9000 and pNZ8112-VP4-LTB/ NZ9000 followed enzyme digestion, PCR identification and sequence analysis.At the same time, we obtained pPG-1-VP4/ L.casei 393 and pPG-1-VP4-LTB/ L.casei 393 by the same way.They also followed enzyme digestion, PCR identification and sequence analysis.
The recombinant strains pNZ8112-VP4 and pNZ8112-VP4-LTB constructed were induced by Nisin in GM17 medium to express interest protein. The expression and localization of the protein from recombinant strains were detected via SDS-PAGE , Western blotting , and immunofluorescence. The lysates of the cells were analyzed by SDS-PAGE. Coomassie blue gel staining showed that 27KD and 40KD fusion protein were expressed in lysates of pNZ8112-VP4 and pNZ8112-VP4-LTB, but not expressed when the same cells were grown in GM17 medium without Nisin . The localization of the VP4 and VP4-LTB protein nisin-induced were analyzed via Western blotting .Immunoreactive bands (27KD,40KD) were detected , and corresponding immunoreactive bands did not display when they were not induced. These results show that Nisin promoter from Lactococcus lactis NZ9000 could efficiently induce the expression of heterologous protein. The immunofluorescence was developed with the mouse anti-VP4 serum. The results indicated that there was green-yellow fluorescence on the cell surface of pNZ8112-VP4 and pNZ8112-VP4-LTB when induced. The cells uninduced did not display an immunofluorescence reaction and were dyed red by Evans blue.
The recombinant strains pPG-1-VP4 and pPG-1-VP4-LTB constructed in this study were induced by lactose in MRS medium to express interest protein. The expression and localization of the protein from pPG-1-VP4 and pPG-1-VP4-LTB were also detected via SDS-PAGE, Western blotting, and immunofluorescence. The lysates of the cells were analyzed by SDS-PAGE. Coomassie blue gel staining showed that 40KD and 53KD fusion protein were expressed in lysates of pPG-1-VP4 and pPG-1-VP4-LTB, but not expressed when the same cells were grown in MRS medium without lactose . The localization of the VP4 and VP4-LTB protein lactose-induced were analyzed via Western blotting .Immunoreactive bands (40KD,53KD) were detected , and corresponding immunoreactive bands did not display when they were not induced. These results show that lactose promoter from L.casei 393 could efficiently induce the expression of heterologous protein. The immunofluorescence was developed with the mouse anti-VP4 serum. The results indicated that there was green-yellow fluorescence on the cell surface of pPG-1-VP4 and pPG-1-VP4-LTB when induced. The cells uninduced did not display an immunofluorescence reaction and were dyed red by Evans blue.
To identify whether the recombinant strains have the ability to induce systemic and mucosal antibody responses, six groups of ten female mice were immunized via oral route with pPG-1, pPG-1-VP4,pPG-1-VP4-LTB,pNZ8112,pNZ8112-VP4 and pNZ8112-VP4-LTB respectively. Every mouse received dose of 109 colony-forming units (c.f.u.)/mL of recombinant strains, respectively. The immune protocol was administered on three consecutive days at days 1,2 and 3. A booster immunization was given at days 17,18 and 19 and a second booster was given at days 33,34 and 35. Serum of mice were collected 7 days after every immunization. Fecal pellets were collected 1, 2, and 7 days after every immunization. Ophthalmic wash were obtained by washing the eyes with 50μL phosphate-buffered saline (PBS) 7 days after every immunization. Vaginal samples were collected by washing the vagina with 200μL PBS 7 days after every immunization . Milk were collected 3、5、7 days after delivery. All samples were stored at–20℃until required.
To maintain homeostasis in the mucosae,different defense mechanisms are involved in permanent and effective surveillance. One of these mechanisms is the secretory immune system through IgA antibodies. IgA prevents the invasion and colonization of pathogenic microorganisms and competes for receptors and metabolic substrates. To assess mucosal immune responses, specific IgA levels in mucosal samples were determined by ELISA. Specific IgA reached a high level in the fecal pellets,ophthalmic and vaginal wash. In contrast,only background levels of antibodies were detected in control animals.The IgA levels of mice administered with pPG-1-VP4 are higher than those administered with pNZ8112-VP4. The IgA levels of mice administered with pPG-1-VP4-LTB are higher than those administered with pNZ8112-VP4-LTB. This is because L.casei 393 has better colonization ability in intestinal tracts than Lactococcus lactis NZ9000. The IgA levels of mice administered with pPG-1-VP4-LTB or pNZ8112-VP4-LTB are higher than those administered with pPG-1-VP4 or pNZ8112-VP4 in fecal, ophthalmic and vaginal samples. This is due to the addition of mucosal immunoadjuvant LTB. This indicates that LTB can enhance the mucosal system response. Vaccines with low immunogenicity in particular require the use of a strong adjuvant to enhance the antigen-presenting .This study has highlighted the potential of LTB as a safe and effective adjuvant.
IgG titers of serum in mice given pPG-1-VP4 or pPG-1-VP4-LTB were similar but higher than the mice given pPG-1. IgG titers of serum in mice given pNZ8112-VP4 or pNZ8112-VP4-LTB were similar but higher than the mice given pNZ8112. In this study, oral administration of recombinant strains displaying VP4 or VP4-LTB protein antigens induced both systemic and mucosal immune responses. Oral immunization elicited specific mucosal responses at the site of gastrointestinal tract, as well as the remote mucosal sites. The IgA antibodies can bind the antigen and minimize its entry with a consequent reduction in inflammatory reactions, which prevents a potentially harmful effect on the tissue . The immune exclusion and elimination of the pathogen at the mucosal surfaces by secretory IgA is crucial in preventing porcine rotavirus .
Freshly isolated mouse splenocytes were seeded at 5×106 cells/mL and incubated for 66 h. 0.5μg/mL,5μg/mL and 25μg/mL VP4 were added to challenge.Cell culture supernatants were harvested and analyzed for the presence of cytokines. Splenic lymphocyte proliferation assay was measured by ELISA. The result indicated that 0.5μg/mL and 5μg/mL VP4 have stronger challenge than 25μg/mL VP4. Interleukin-4 (IL-4) and gamma interferon (IFN-γ) cytokine assays were performed using Biosource ELISA kits according to the manufacturer’s instructions. The result indicated that all immunized groups secreted significantly more IL-4 and IFN-γthan the control group.Significant differences were seen among the groups. Immunized mice secreted increased levels of IL-4 that were significantly higher than IFN-γ. Overall, these data show that immunization of recombinant strains via oral route produced significant innate-type cytokine responses. It suggested that enhanced protection against infection of rotavirus .
Furthermore, we collected the milk of mice 3、5、7 days after delivery.Specific IgA in the milk were detected by ELISA.The result indicated that there were high levels of specific IgA in the samples.It shows that antibodies produced by administration with recombinant strains can serve passive immunoprotection to the immature animals.
In conclusion , the results obtained so far demonstrate that Lactococcus lactis and lactobacillus are capable of delivering antigen to the mucosal and systemic immune systems following oral immunization. Lactic acid bacteria as vaccine delivery vehicles are able to colonize different mucosal sites such as gastrointestinal tracts, genital tracts and could thus be used specifically to vaccinate against pathogens at their site of entry. Their harmLess nature make them more appropriate as an oral vaccine carrier to deliver heterologous antigens. The recombinant strains have better immunogenicity and can elicit stronger specific mucosal immune responses and systematic immune responses. When VP4 was co-expressed with LTB, it showed much stronger mucosal immune responses. It indicated that LTB with qualified immunoreactivity, antigenicity and adjuvanticity could be used to develop genetically engineered vaccine. It should be suitably applicable as an immunoadjuvant for mucosal vaccines.All theses work established a good foundation for further study on the new and effective recombinant oral vaccine of porcine rotavirus.
引文
巴德年,主编. 1998.当代免疫学技术与应用[M].北京:北京医科大学中国协和医科大学联合出版社,23-29.
程健频,李昌铭,魏锦龙. 2005,仔猪轮状病毒性腹泻的调查与防治[J].甘肃畜牧兽医, 35(5):28-29.
冯建民. 1997,生物工程进展, 17(6):48-50.
甘慧泉. 2004,黏膜免疫及其在疫苗研制中的应用[J].热带医学杂志, 4(6):763-765.
高明. 1996,微生物学免疫学进展, 24 (4):67-69.
宫德正,邹原,梅华. 2002,肠黏膜免疫系统与细胞因子[J].大连医科大学学报, 24(1): 56-60.
龚非力主编. 2004.医学免疫学[M].第2版.北京:科学出版社,72-73,381.
郭兴华. 2002,益生菌基础与应用[M].北京:北京科学技术出版社.
郭鹰,邹全明,朱永红,吴超,郭刚,毛旭虎,袁小澎. 2004,BALB/c小鼠口服幽门螺杆菌疫苗rLTB-HspA的免疫应答[J].免疫学杂志,20(3):201-207.
侯强红,余兴龙,李微,李润成,罗维,刘浩,尹恒,刘忠华. 2007,猪圆环病毒2型
Cap蛋白部分基因序列与大肠杆菌LTB成熟肽基因的融合表达及免疫原性研究[J].中国预防兽医学报,29(11):847-851.
胡东兴,潘康成. 2001.微生态制剂及其作用原理.中国饲料,3:14-16.
李理. 2004,医学分子生物学杂志, 1(5):316-319.
李忠明. 2001,当代新疫苗[M].北京:高等教育出版社,2-175.
刘正祥,邹全明,洪愉,郭桐生,郭鹰,曾韦锟. 2004,幽门螺杆菌粘附素与大肠杆菌LtB融合疫苗的口服免疫与预防试验[J].中国人兽共患病杂志, 20(7):577-581.
庞其方,丘富禧,俞富荣. 1979.婴幼儿秋季急胃肠炎病原的轮状病毒的研究.中华医学杂志. 59 589-591
彭世勇,王健伟,温乐英. 2002.人类轮状病毒基因DNA免疫的初步研究.中国病毒学. 17(1) 38-41
全胜,严杰.2003.重组大肠杆菌不耐热肠毒素B亚单位基因表达系统构建[J].微生物杂志,2,14-15.
任贵强,张七斤,张和平. 2006,饲喂乳酸菌对小白鼠血清中IgG及肠道中slgA影响的研究[J].中国畜牧兽医, 33(5):64-67.
阮孟斌,朱明月,周鹏. 2004,外源基因在乳酸菌中的表达[J].应用与环境生物学报, 10(4):526-529.
王春风,秦泽荣,孙哲. 2001.以thyA为选择压力非抗性质粒载体的构建.微生物学通报,28(2):42-45.
王春凤,秦泽荣,徐镔蕊. 2002,饲喂转球虫基因功能乳酸杆菌后对雏鸡体重的影响[J].畜牧兽医学报, 33(6):591-593.
吴超,冯强,曾韦锟,郭桐生,高志刚,邹全明. 2005,重组大肠杆菌不耐热肠毒素B
亚单位的表达、纯化及黏膜佐剂活性研究[J].中华微生物学和免疫学杂志,25(4):307-311.
吴正均,叶锦,郭本恒.2004.乳酸菌的抗高血压作用.乳品科学与技术.1:1-8.
肖玮,钱渊,张又. 1999,引起产科新生儿腹泻暴发的轮状病毒株VP4、VP7编码基因与其毒力关系的探讨.病毒学报,15(4):314-321.
肖玮,钱渊. 1998,人A组轮状病毒北京地方株VP4血清烈特异片段编码基因的序列分析.微生物学报,38(3):197-203.
杨国峰,周鹏,王健伟. 2001.轮状病毒疫苗的研究进展及其转基因植物疫苗的开发前景.生物技术通报. (1) 16-19.
杨汉春. 2002,动物免疫学[M].第二版.北京:中国农业大学出版社, 91-93.
杨志军,韦隆华,唐俊杰.麻疹疫苗及加佐剂经滴鼻免疫小鼠的抗体应答[J].贵阳医学院学报,2005,30(1):23-25.
殷震,刘景华. 1997.动物病毒学.第二版.科学出版社,562-571
张二芹,李世访,王春凤等. 2006,转猪轮状病毒VP6基因烟草植物的获得[J].中国兽医学报,(2):173-174.
张和平,张七斤,孟和毕力格. 2006,L.case Zhang对小鼠T淋巴细胞亚群及血清IgG和肠黏膜SlgA的影响[J].中国乳品工业,34(10):4-8.
张雷,卫广森. 2005,猪轮状病毒感染研究进展[J].现代畜牧兽医,(4): 42-44.
张茂林,刘红丽,余兴龙,涂长春,扈荣良,邹啸环,郭学军,殷震. 2004,大肠杆
菌不耐热肠毒素对狂犬病病毒减毒疫苗株黏膜免疫效应的增强作用[J].中国兽医学报, 24(1):39-41.
赵长安. 1998,轮状病毒感染的研究现状[J].国外医学—流行病学传染病学分册, 25(4):145-148.
周旭,李益民,侯玲. 1999.轮状病毒DNA疫苗的制备及其抗体应答[J].中国生物制品学杂志,12(2):72-74.
Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al. 1999. Persistence of colonization of human colonicmucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbial. 65: 351-354.
Allison GE,Klaenhammer TR. 1996. Functional analysis of the gene encoding immunity to lactacin F, Lafl, and its use as a Lactobacillus-specific,food-grade genetic marker. Appl Environ Microbiol. 62(12):4450-4460.
Alvarez S. 1998, Specific immunity induction at the mucosal level by viable Lactobacillus casei: a perspective for oral vaccine development[J].Food and Agricultural Immunology, 10:79-87.
Apostolaki,Maria Williams,Neil A. 2004,Nasal Delivery of Antigen with the B Subunit of Escherichia coli Heat-Labile Enterotoxin Augments Antige-Specific T-Cell Clonal Expansion and Differentiation[J].Infection and Immunity, 72(7):4072-4080.
Ball JM, Hardy ME, Atmar RL, et al. 1998,Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal ,immune response in mice[J]. J Virol,72(2):1345.
Barman N N, Barman B, Sarma D K, et al. 2003,Prevalence of rotavirus, transmissible gastroenteritis virus and porcine epidemic diarrhoea virus antibodies in pigs of Assam, India[J].The Indian Journal of Animal Sciences, 73(6): 576-578.
BERMUDEZ-HUMARAN L G, LANGELLA P, MIYOSHI A, et al. 2002,Production of human papilloma virus type 16 E7 protein in Lactococcus lactis[J]. Appl Environ Microbiol, 68(2): 917-922.
BOLOTIN A, WINCKER P, MAUGER S, et al. 2001, The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. Lactis IL1403[J]. Genome Res, 11(5): 731-753.
Bouhnik Y, Flourie B, Andrieux C, Bisetti N, Briet F, Rambaud JC. 1996. Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans. Eur J Clin Nutr, 50(4): 269-273.
Bradney C P, Sempowski G D, Liao H X, et al. 2002,Cytocines as aduvants for the induction of anti-immunodeficiency virus peptide immunoglobulin Gand IgA antibodies in serum and mucosal secretions after nasal immunization[J].J Virol, 76(2):517-524.
Brandtzag P. 1994.Distribution and characteristics of mucosal immunoglobuilin-producing cell. In: Handbook of immunology. Boston: Academic Press, p.251-279.
Bron PA,Benchimol MG, Lambert J,Palumbo E,et al. 2002. Use of the alr gene as a food-grade selection marker in lactic acid bacteria. Appl Environ Microbiol, 68(11):5663-5670.
CARDENAS FREYTAG L ,CHENG E, MAYEUX P,et al. 1999, Effectiveness of a vaccine composed of heat-killed candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis[J]. Infect Immun, 67(2):826-833.
CHASSY B M,GIBSON E,GIUFFRIDA A. 1976, Evidence for extrachromsomal elements in Lactobacillus[J]. J Bacterial, 127(3): 1576-1578.
Cheng E, Cardenas-Freytag L, Clements JD.1999,The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin(LT)[J]. Vaccine, 18(1-2):38.
CHEUN H I, KAWAMOTO K, HIRAMATSU M, et al. 2004, Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection[J]. Appl Microbiol, 96(6):1347-1353.
Childers N K, Miller K L,Tong G, et al. 2000, Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antiger[J]. Infect Immune, 68(10):5509~5516.
Clark F,et al. 1986,Am J Dis Child, 140:350-356.
Conner M E, Zarley C D, Hu B. 1996. Virus-like particles as a rotavirus subunit vaccine. Infect Dis. 174(2) 88-92.
de RUYTER P G, KUIPERSO P, de VOSW M. 1996,Controlled gene expression systems for Lactococcus lactis with the food-grade inducer-nisin[J]. Appl Environ Microbiol, 62(10): 3662-3667.
De Simone C.,Vesely R.,Bianchi-Salvadori B.et al.1993.The role of Probiotics in modulation of the imrnune system in man and in animals.International journal of immunotherapy,9:23-28.
De VOSW M. 1999, Gene expression systems for lactic acid bacteria[J].Curr Opin Microbiol, 2(3): 289-295.
Delves BJ. 1990. Nisin and its uses as a food preserva tive. Food Technol, 44(11): 100-17.
Dewey C, Carman S, Pasma T, et al. 2003,Relationship betwee group A porcine rotavirus and management practices in swine herds in Ontario[J].The Canadian Veterinary Journal, 44(8): 649-653.
DROUAULT S, CORTHIER G, EHRLICH S.D, et al. 1999,Survival physiology, and lysis of Lactococcus lactis in the digestive tract[J]. Appl Environ Microbiol, 65: 4881-4886.
Dunn S J, Fiore L, Werner R L, et al. 1995, Imrrmnogenecity, antigenicity,and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5 and VP8 from rhesus rotavirus [J]. Arch. Virol, 140:1969-1978.
Eequivel F R, Lopez S, Arias C. 2000. The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response. Arch Virol. 145(4):813-825
ENOUFV, LANGELLA P, COMMISSAIRE J, et al. 2001, Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic[J]. Appl Environ Microbiol, 67 (4): 1423 -1428.
Estes M K, Cohen J. 1989. Rotavirus gene structure and function. Microbiol Rev. 53(4) 410-449.
Eva Medina, Carlos Alberto Guzman. 2001. Use of live bacterial vaccine for antigen delivery: potential and limitations. Vaccine, (19): 1573-1580.
Fujihashi K, Koga T, Van G F W, et al. 2002, A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-base adjuvants [J]. Vaccine, 20 (19-20):2431-2438.
Gil Mt, de Souza C O, Asensi M, et al. 2000, Asensi M, et al. Homotypic protection againstrotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8 subunit of the VP4 capsid protein[J]. Viral Immunol, 13(2): 187-200.
GILBERT C, ROBINSON K, Le PAGE RW, et al. 2000, Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis [ J]. Infect Immun, 68(6): 3251-3260.
Gilland S.E.,Nelson C.R. and Maxwell C.1985.Assimilation of cholesterol by Lactobacillus acidolphilus.Applied and Environmental Microbiology,49(2):377-381.
Gluck U, Gebbers JO, Gluck R. 1999,Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers[J]. J Virol, 73(9):7780.
Grangette C, Muller-Alouf H, Hols P, et al. 2004, Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria[J]. Infect Immun, 72(5): 2731-2737.
Haller D.,Bode;Hummes.wp,et al.1999,Cytokine Secretin by Stimulated Monoeytes Dependson the Growth Phase and Heat Treatment of Bacteria:A comparative Study between LABtic Acid Bacteria and Invasive Pathogens[T]Microbiol Immunol, 43(10):925-935.
Harrod T, Martin M , Russell M W. 2001, Long-term persistence and recall of immune responses in aged mice after mucosal immunization [J]. Oral Microbiology and Immunology, 16(3):170-177.
Hauer AC, Breese EJ, Walker Smith JA,et al. 1997,The frequency of cells secreting interferonγ, IL-4, IL-5 and IL-10 in the blood and duodenal mucosa of childrenwith cow’s milk hypersensitivity [J]. Pediatr Res, 42(1):1-10.
Herrmann J E, Chen S C, Fynan E F. 1996. Protection against rotavirus infections by DNA vaccination. Infect Dis. 174(l) :93-97.
Hesse R A, Couture L P, Ellsworth S R. 1993, Production and characterization of VP4/VP7 reassortant swine rotaviruses derived from Gottfried and OSU parental strains[J]. Am J Vet Res 54(10): 1623-1629.
Hiroi T, YanagitaM, IijimaH,et al. 1999, Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cellinmucosa-associatedtissues[ J] . JImmunol, 162(2):821-828.
HO PO,WANG J K, LEE Y K. 2005,Intragastric administration of Lactobacillus casei expressiong transmissible gastroenteritis coronavirus spike glycoprotein induced specific antibody production [J]. Vaccine, 23: 1335-1342.
Ijaz M K, Attah-Piku S K, Redmond M J, et al. 1991, Heterotypic passive protection induced by synthetic peptides corresponding to VP7 and VP4 of bovine rotavirus[J]. J Virol, 65: 3106-3113.
Ijaz M K, Nur-E-Kamal M S A, Dar F K, et a1. 1998,Inhibition of rotavirus infection in vivo ans in vitro by a synthetic peptide from VP4[J].Vaccine, 16: 916-920.
Jin L.Z.,Ho Y.W.,Abdullah N.and Jalaludin S.1998.Growth Performance,intestinal microbial populations,and serum cholesterol of broilers fed diets containing lactobacillus cultures.Poultry Science,77:1259-1265.
Johnson M A, Misra R M, Lardelli M. 1989. Synthesis in Escherichia coli of the major glycoprotein of human rotavirus: analysis of the antigenic regions. Gene. 84(1) 73-81
Jos FML Seegers. 2002. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends in Biotechnology, (20): 508-515.
Kapikian A Z,Chanock R M. 1996. Rotaviruses. Field Virology. 3rd ed. New York, 1657-1660 Kapikian AZ,et al. 1986,11th Nobel Conference (Stockholm).Lund, Sweden:Student-litteratur, 192-214.
Kirjavainen PV, Tuomola EM,Crittenden RG, et al. 1999. In vitro adhesion and platelet aggregation properties of bacteremia-associated lactobacilli [J]. Infect Immun, 67: 2653- 2655.
Klaver F.A.M.& van der Meer R.1993.The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium is due to their bile salt deconjugation activity.Environmental Microbiology,59:1120-1124.
Korpela R, Moilanen E, Saxelin M, Vapaatalo H. 1997. Lactobacillus rhamnosus GG (ATCC 53103) and platelet aggregation in vitro. Int J Food Microbiol, 37(1): 83-86.
Kovacs-Nolan J, SasakiE,Yoo D, et al. 2001, Cloning and expression of human rotavirUS spike protein, VPB, in Escherichia coli[J]. Biochem Biophys Res Commun, 282: 1183-1188.
Kushal R.,Anand S.K.&Chander H.2006.Effect of feeding miero-entrapped co-culture of Lactobacillus acidophilus and Bifidobacterium bifidum on the immune response and protection of mice infected with Salmonella typhimurium.Dairy Science and Technology,86:387-399.
Lamonica R,Kocer S,Nazarva J,et al. 2001,VP4 differentially regulates TRAF2 signaling disengaging JNK activation while directiong NF.αβto effect rotavirus-specific cellular responses [J]. J Biol Chem, 276(23):19889-19896.
LANGELLA P, Le LOIR Y. 1999, Heterologous protein secretion in Lactococcus lactis: a novel antigen delivery system [ J]. Braz J Med Biol Res, 32(2): 191-198.
LANGELLA P. 2001,Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis[ J]. Appl Microbiol Biotechnol, 67, 4119-4127.
Lee CK. 2001,Vaccination against Helicobacter pylori in non-human primate models and humans[J]. Scand J Immunol, 53(5):437.
Lee YK, Ho PS, Low CS, et al. 2004. Permanent colonization by lactobacillus casei is hindered by the low rate of cell division in mouse gut. Appl Environ Microbial, 70: 670-674.
LEEM H, ROUSSEL Y, WILK S M, et al. 2001, Expression of Helicobacter pyloriurease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice[J]. Vaccine, 19(28-29): 3927-3935.
Li TK, Fox BS. 1996, Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone [J]. Int Immunol, 8(12):1849-1856.
Liu M, Offit P A, Estes M K. 1988. Idetification of simian rotavirus SAII genome segment 3 product. Virol. 163 :26-32
Lorenz S, Monique V, Adrian W, et al. 2002, Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle[J]. Vaccine, 20: 2913-2920.
Maassen C B M, Laman J D, Heijne den Bak-G lashouwer M J, et al. 1999, Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination ormyelin proteins for oral tolerance induction in multiple sclerosis[J]. Vaccine, 17: 2117-2128.
Maria Leonor S O liveria, Vicente Monedero, Eliane N Miyaji, et al. 2003,Expression of Streptococcus pneumoniae antigens, PsaA and PspA by Lactobacillus casei[J]. FEMS Microbiol Lett, 227:25-31.
MARIA LEONOR,OLIVEIRA S,VICENTE MONEDERO, et al. 2003, Expression of Streptococcus pneumoniae antigens,PsaA(pneumococcal surface antigen A) and PspA(pneumococcal surface protein A) by Lactobacillus casei[J]. FEMS Microbiology Letters, 227: 25-31.Mark K. H. Hoblet, L. J. Saif, E. M. Kohler. 1986,Am J Vet Res. 47∶1697-1703
Mcghee JR, Mestecky J, Dertzbaugh MT, Eldridge JK, Hirasawa M, Kiyono H. 1992. The Mucosal immune system: from fundamental concepts to vaccine development. Vaccine, 10:75-88.
McNeal M M, VanCott J L, Choi A H, et al. 2002, CD4+ T cells arethe only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G)[J]. J Virol, 76(2):560-568.
McNeal MM, Vancott JL, Choi AH, et al. 2002,CD+T cells are the onllymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with achimeric VP6 protein and the adjuvant LT(R192G)[J]. J Virol, 76(2):560.
MICHAEL THEISEN, SOE SOE, KATJA BRUNSTEDT, et al. 2004, A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies [J].Vaccine, 22(9-10): 1188-1198.
Millar DG, HirstTR, Snider DP. 2001,Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin[J]. Infect Immun, 69(5):3476-3482.
MONNE M,CHAN K W, SLOTBOOM D J, et al. 2005, Functional expression of eukaryotic membrane proteins in Lactococcus lactis[J]. Protein Sci, 14: 3048-3056.
Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. 2003,The first rotavirus vaccine and intussusception:epidemiological studies and policy decisions[J].J Infect Dis, 187 (8):1309-1313.
Muscettola M,Massai L,Tanganelli C,et al. 1994,Effects of Lactobacilli on interferon Product in young and aged mice[J]. Annals New York Academy of science, 717:227-232.
NaiduA.S, Bidlack W.R.&Clemens R.A. 1999. Probiotie spectra of laetic acid bacteria(LAB). critical Reviews in Food Science and Nutrition,39:3-126.
Nakagawa I, Takahashi I, Kiyono H,et al. 1996,Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early TH1 and late TH2 cytokine expression in Peyer’s patches [J]. J Infect Dis, 173(6):1428-1436.
Nakamura Y, Yamamoto N, Sakai K, Okubo A, et al. 1995. Purification and characterization of angiotensin l-converting enzyme inhibitors from sour milk. J Dairy Sci, 78(4): 777-783.
Nashar TO,Webb HM,Eaglestone S,et al. 1996,Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin:receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci USA., 93(1):226-230.
Nes IF, Diep DB, Havarstein LS, Brurberg MB, Eijsink V, Holo H. 1996. Biosynthesis of bactericins in lactic acid bacteria. Antonie Van Leeuwenhoek, 70: 113-128.
NORTON P M, Le PAGE R W, WELLS JM. 1995, Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system[J]. Folia Microbiol, 40(3): 225-230.
NOUAILLE S, RIBEIRO L A, MIYOSHIA, et al. 2003, Heterologous protein production and delivery systems for Lactococcus lactis[J]. Genet Mol Res, 2(1): 102-111.
O’Sullivan M.G.,Thornton G.,O’Sullivan G.C.et al.1992.Probiotic bacteria:myth or reality.trendfood technology ,3:309-314.
Offit P A, Clark H F. 1985, Protection against rotavirus-induced gastroenteritis in a murine model by passively-acquired gastrointestinal but not circulating antibodies[J].J Virol, 54:58-64.
Ong Kong-Wee,Wilson A,Douglas Hirst,et al. 2003, The B Subunit of Escherichia coli Heat-Labile Entero toxin Enhances CD8+ Cytotoxic-T-Lymphocyte Killing of Epstein-Barr Virus-Infected Cell Lines[J]. Journal of Virology, 77(7):4298-4305.
Padilla-Noriega L, Fiore L, Rennels M B, et al. 1997,Humoral immune responses to VP4 and its cleavage products VP5 and VP8 in infants vaccinated with rhesus rotavirus[J].J Vivol, 30: 1392-1397.
Percira D.I.,Gibson G.R.2002.Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Applied and Environmental Microbiology, 68(9):4689-4693.
Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N. 1995. Immune system stimulation by probiotics. Journal of Dariy SCI, 78: 1597-1606.
Perdigon G, Fuller R, Raya R. 2001, Lactic acid bacteria and their effect on the immune system [ J]. Curr Issues Intest Microbiol, 2(1): 27- 42.
Perdigon G,Alvarez S,Rachid M. 1995,Immune system stimulation by Probiotics[J],Journal of Dairy Science, 78:597-1606.
Perdigon G,Alvarez S. 1991,Immunoadjuvant activity of oral Lactobacillus casei:influence of dose on the secretory immune response and protective capacity in intestinal infections[J].Jounal of Dairy Reseaeh, 58(2):485-496.
Perdigon G, de Macias ME, Alvarez S,et al. 1998,Systemic augmentation of the immune response in mice by feeding fermented milk with Lactobacillus casi and Lactobacillus acidophilus[J].Immunology, 63:17-23.
Perdigon G., Medici M.,de Jorrat B.B.et al.1993.Immunomodulating effects of lactic acid bacteria on mucosal and tumoral immunity.International Journal of lmmunotherapy, 9(11):29-52.
Perdigon G., Nader de Macias M.E.,Alvarez S.et al.1990.Prevention of gastrointestinal infection using immunobiological methods with milk fermented with Lactobacillus.Journal of Dairy Research,57:255-264.
Peter H.Pouwels, Rob J.Leer, Michael Shaw, et al. 1998. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. International Journal of Food Microbiology,(41):155-167.
Pierce NS,Gowans JL. 1975,Cellular kinetics of the intestineal immune response to cholera toxoid in rats.J.Exp.Med., 142:1550-1563.
Pizza M, Giuliani M, FontanaM, et al. 2001, Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine, 19: 2534-2541.
PONTES D S, DORELLA F A, RIBEIRO L A, et al. 2003, Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7 /L12 antigen[J]. J Drug Target, 11(8-10): 489-493.
Portugal R.L.,Goncalves J.L.,Fernandes L.R.et al.2006.Effect of Lactobacillus delbrueckii on cholesterol metabolism in germfree mice and on atherogenesis in apolipoprotein E knock-out rnice.Brazilian Journal of medical and Biological Reseach,39:629-635.
Posno M,Heuvelmans PT,van Giezen MJ,et al. 1991. Complementation of the inability of Lactobacillus strains to utilize D-xylose with D-xylose catabolism-encoding genes of Lactobaci-llus pentosus. Appl Environ Microbiol, 57(9):2764-2766.
Pouwel PH, Rob J. 1996, The potential of Lactobacillus as a carrier for oral immunization: Development and preliminary characterization of vector systems for targeted delivery of antigen[ J]. Biotechnology, 44: 183-192.
Prasad BV, Wang G J, Cler JPM. 1988. Three-demessional structure of rotavirus[J]. Mol Biol. 199 269-275
Racz M L, Kroeff S S, Munford V. 2000. Molecular characterization of porcine rotaviruses from the southern region of Brazil: characterization of an atypical genotype G9 strain[J]. Clin Microbiol. 38(6) 2443-2446
RAHA A R, VARMA N R, YUSOFF K, et al. 2005, Cell surface display system for Lactococcus lactis: a novel development for oral vaccine [J]. Appl Microbiol Biotechnol, 1(6). Ramsay A J, Husband A J, Ramshaw I A,et al. 1994,The role of interleukin-6 in mucosal IgA antibody responses in vivo[J]. Science, 264(5158):561-563.
Rao C D, Gowda K, Reddy B S. 2000. Sequence analysis of vp4 and vp7 genes of nontypeable strains identifies a new pair of outer capsid proteins representing novel P and G genotypes in bovine rotaviruses [J]. Virology. 276(1) 104-113
RAVN P, ARNAU J, MADSEN S M, et al. 2000, The development of TnNuc and its use for the isolation of novel secretion signals in Lactococcus lactis[J]. Gene, 242(1-2): 347-356.
RAVN P, ARNAU J, MADSEN S M, et al. 2003, Optimization of signal peptide SP310 for heterologous protein production in Lactococcus lactis [J]. Microbiology, 149: 2193-2201.
Renner Hw, Munzner R. 1991. The possible role of probiotics as dietary antimutagen. Mutat Res. 262(4): 239-245.
Reveneau N, Geoffroy M C, Locht C, et al. 2002, Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations[J]. Vaccine, 20: 1769-1777.
Rodak L,Valicek L,et al. 2005,An ELISA optimized for porcine epidemic diarrhoea virus detection in faeces[J]. Vet Microbiol, 105(1):9-17.
ROLLWAGEN FM , PACHECO ND , CLEMENTS JD,et al. 1993,Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant[J]. Vaccine, 11(13): 1316-1320.
Roy P. 1996. Genetically engineered particularte virus-like struvtures and their use as vaccine delivery systerns. Intervirology. 39 62-64.
Salminen S.& Deighton M.1992.Lactic acid bacteria in the gut in normal and disorderedstates.Digestive Diseases,10:227-238.
Sandino A M, Jashes M, Faundex G. 1985. Role of the inner protein capsid on invitro human rotavirus transcription[J]. Gen Virol. (60),797-802.
Sereno M M, Gorziglia M I. 1994. The outer capsid protein VP4 of murine rotavirus Eb represents a new P type. Virol. (199),500-504.
Shaw DM, Gaerthe B, Leer RJ, et al. 2000. Engineering the miroflora to vaccine the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing Lactobacilli. Immunology. 100:510-518.
Shing C. Chen,David H. Jones, Ellen F. Fynan,et al . 1998,Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles [J]. J Virol, 72(7) ,5757-5761.
Stannard L M. 1977. Observation on the morPHology of two rotaviruses. Gen.Virol. (37) 435-441.
Stobie L, Gurunathan S, Prussinc,et al. 2000,The role of antigen and IL-12 in sustaining TH1 memory cells in vivo: IL-12 is required to maintain memory/effector TH1 cells sufficient to mediate protection to an infectious parasite challenge [J].Proc Natl Acad Sci USA, 97(15):8427-8432.
Takahashi H, Sasaki K, Takahashi M. 2006,Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice[J]. Vaccine, 24(17):3591-3598.
Takala M, Saris J, Tynkkynen H. 2003. Food-grade host/vector expression system for Lactobacillus casei based on complementation of Plasmid-associated phospho-beta-galactosidase gene lacG. Appl Microbiol Biotechnol, 60(5):564-570.
Taranto MP, Medici M, Perdigon G, Ruiz Holgado AP. 2000. Effect of lactobacillus reuteri on the prevention of hypercholesterolemia in mice. J Dairy Sci, 83(3): 401-403.
Thoreux K,Schmucker DL. 2001,Kefir milk enhances intestinalimmunity in young but not old rats.J Nutr, 131:807-812.
Tomohiko Ogawa, Yasuyuki Asai, Kenji Yasuda, et al. 2005,Oral immuno-adjuvantactivity of a new symbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice[J]. Nutrition Research, 25: 295-304.
Tomohiko Ogawa, Yasuyuki Asai, Kenji Yasuda, Hiromi Sakamoto. 2005.Oral immunoadjuvant activity of a new symbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice. Nutrition Research, (25): 295-304.
Truitt RL, Hanke C, Radke J,et al. 1998,Glycosphingolipids as novel targets for T-cell suppression by the B subunit of recombinant heat-labile enterotoxin [J]. Infect Immun, 66(4):1299-1308.
Tumpey TM, Renshaw M, Clements JD, et al. 2001,Mucosal delivery of inactivated influenzavaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection[J]. J Virol, 75(11):5141.
Tuomola EM, Ouwehand AC, Salminen SJ. 1999. Human ileostomy glycoproteins as a model for small intestinal mucus to investigate adhesion of probiotics [J]. Lett Appl Microbiol, 28: 159- 163.
Valenzuela S, Pizarro J, Sandino A M. 1991. PHotoaffinity labeling of rotavirus VP1 with 8-azido-ATP: identification of the viral RNA polymerase [J]. Gen Virol. 65 3964-3967. Vesikari T, et al. 1983,Lancet, 11:807-811.
Vollaard E J, Clasener H A. 1994. Colonization resistance. Antimicrob Agents Chemother, 38(3): 409-414.
Wang L, Huang J A, Nagesha H S. 1999. Bacterial expression of the major antigenic regions of porcine rotavirus VP7 induces a neutralizing immune response in mice. Vaccine. 17(20-21) 2636-2645
Ward RL. 2003,Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model[J].Viral Immunol, 16(1):17-24.
WELLS JM, WILSON P W, et al. 1993, Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge[J]. Mol Microbiol, 8(6): 1155-1162.
Williams NA,Hirst TR,and Nashar TO.1999,Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.Immunology Today, 20(2):95-101.
Wu YY, Nahm MH, Guo Y, et al. 1997,Intranasal immunization of mice with PspA(pneumococcal surface protein A can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae[J]. J Infect Dis, 175:839.
WuYZ,Li JT,Mou ZR,et al. 2003.Oral immunization with rotavirus VP7 expressed intransgenic potatoes induced high titers of mucosal neutralizing IgA.Virology. 313(2):337-342.
Yamamoto M, Vancott JL, Okahashi N, et al. 1996,The role of Thl and Th2 cells for mucosal IgA responses[J]. Ann NY Acad Sci, 778:64.
Yankelevich B, Soldatenkov VA, Hodgson J,et al. 1996, Differential induction of programmed cell death in CD8+and CD4+T cells by the B subunit of cholera toxin[J]. Cell Immunol, 168(2):229-234.
Yasui H,Mike A,Ohwaki M.Immunogenicity of Bifidobacterium breve and change in antibody production in Peyer,s patches after oral administration[J].Journal of Dairy Scienee,199,72:30.
Yoo D, Lee J, Harland R, et a1. 1997, Material immunization of pregnant cattle with recombinant VP8 protein of bovine rotavirus elicits neutralizing antibodies to multiple serotypes Colostral neutralizing antibody by rotavirus VP8[J]. Adv Exp Med Biol, 412:405-411.
Zijlstra RT, Odle J, Hall WF, Petschow BW, et al. 1994 ,Effect of orally administered epidermal growth factor on intestinal recovery of neonatal pigs infected with rotavirus [J].J Pediatr Gastroenterol Nutr, 19(4):382-390.
程健频,李昌铭,魏锦龙. 2005,仔猪轮状病毒性腹泻的调查与防治[J].甘肃畜牧兽医, 35(5):28-29.
冯建民. 1997,生物工程进展, 17(6):48-50.
甘慧泉. 2004,黏膜免疫及其在疫苗研制中的应用[J].热带医学杂志, 4(6):763-765.
高明. 1996,微生物学免疫学进展, 24 (4):67-69.
宫德正,邹原,梅华. 2002,肠黏膜免疫系统与细胞因子[J].大连医科大学学报, 24(1): 56-60.
龚非力主编. 2004.医学免疫学[M].第2版.北京:科学出版社,72-73,381.
郭兴华. 2002,益生菌基础与应用[M].北京:北京科学技术出版社.
郭鹰,邹全明,朱永红,吴超,郭刚,毛旭虎,袁小澎. 2004,BALB/c小鼠口服幽门螺杆菌疫苗rLTB-HspA的免疫应答[J].免疫学杂志,20(3):201-207.
侯强红,余兴龙,李微,李润成,罗维,刘浩,尹恒,刘忠华. 2007,猪圆环病毒2型
Cap蛋白部分基因序列与大肠杆菌LTB成熟肽基因的融合表达及免疫原性研究[J].中国预防兽医学报,29(11):847-851.
胡东兴,潘康成. 2001.微生态制剂及其作用原理.中国饲料,3:14-16.
李理. 2004,医学分子生物学杂志, 1(5):316-319.
李忠明. 2001,当代新疫苗[M].北京:高等教育出版社,2-175.
刘正祥,邹全明,洪愉,郭桐生,郭鹰,曾韦锟. 2004,幽门螺杆菌粘附素与大肠杆菌LtB融合疫苗的口服免疫与预防试验[J].中国人兽共患病杂志, 20(7):577-581.
庞其方,丘富禧,俞富荣. 1979.婴幼儿秋季急胃肠炎病原的轮状病毒的研究.中华医学杂志. 59 589-591
彭世勇,王健伟,温乐英. 2002.人类轮状病毒基因DNA免疫的初步研究.中国病毒学. 17(1) 38-41
全胜,严杰.2003.重组大肠杆菌不耐热肠毒素B亚单位基因表达系统构建[J].微生物杂志,2,14-15.
任贵强,张七斤,张和平. 2006,饲喂乳酸菌对小白鼠血清中IgG及肠道中slgA影响的研究[J].中国畜牧兽医, 33(5):64-67.
阮孟斌,朱明月,周鹏. 2004,外源基因在乳酸菌中的表达[J].应用与环境生物学报, 10(4):526-529.
王春风,秦泽荣,孙哲. 2001.以thyA为选择压力非抗性质粒载体的构建.微生物学通报,28(2):42-45.
王春凤,秦泽荣,徐镔蕊. 2002,饲喂转球虫基因功能乳酸杆菌后对雏鸡体重的影响[J].畜牧兽医学报, 33(6):591-593.
吴超,冯强,曾韦锟,郭桐生,高志刚,邹全明. 2005,重组大肠杆菌不耐热肠毒素B
亚单位的表达、纯化及黏膜佐剂活性研究[J].中华微生物学和免疫学杂志,25(4):307-311.
吴正均,叶锦,郭本恒.2004.乳酸菌的抗高血压作用.乳品科学与技术.1:1-8.
肖玮,钱渊,张又. 1999,引起产科新生儿腹泻暴发的轮状病毒株VP4、VP7编码基因与其毒力关系的探讨.病毒学报,15(4):314-321.
肖玮,钱渊. 1998,人A组轮状病毒北京地方株VP4血清烈特异片段编码基因的序列分析.微生物学报,38(3):197-203.
杨国峰,周鹏,王健伟. 2001.轮状病毒疫苗的研究进展及其转基因植物疫苗的开发前景.生物技术通报. (1) 16-19.
杨汉春. 2002,动物免疫学[M].第二版.北京:中国农业大学出版社, 91-93.
杨志军,韦隆华,唐俊杰.麻疹疫苗及加佐剂经滴鼻免疫小鼠的抗体应答[J].贵阳医学院学报,2005,30(1):23-25.
殷震,刘景华. 1997.动物病毒学.第二版.科学出版社,562-571
张二芹,李世访,王春凤等. 2006,转猪轮状病毒VP6基因烟草植物的获得[J].中国兽医学报,(2):173-174.
张和平,张七斤,孟和毕力格. 2006,L.case Zhang对小鼠T淋巴细胞亚群及血清IgG和肠黏膜SlgA的影响[J].中国乳品工业,34(10):4-8.
张雷,卫广森. 2005,猪轮状病毒感染研究进展[J].现代畜牧兽医,(4): 42-44.
张茂林,刘红丽,余兴龙,涂长春,扈荣良,邹啸环,郭学军,殷震. 2004,大肠杆
菌不耐热肠毒素对狂犬病病毒减毒疫苗株黏膜免疫效应的增强作用[J].中国兽医学报, 24(1):39-41.
赵长安. 1998,轮状病毒感染的研究现状[J].国外医学—流行病学传染病学分册, 25(4):145-148.
周旭,李益民,侯玲. 1999.轮状病毒DNA疫苗的制备及其抗体应答[J].中国生物制品学杂志,12(2):72-74.
Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al. 1999. Persistence of colonization of human colonicmucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbial. 65: 351-354.
Allison GE,Klaenhammer TR. 1996. Functional analysis of the gene encoding immunity to lactacin F, Lafl, and its use as a Lactobacillus-specific,food-grade genetic marker. Appl Environ Microbiol. 62(12):4450-4460.
Alvarez S. 1998, Specific immunity induction at the mucosal level by viable Lactobacillus casei: a perspective for oral vaccine development[J].Food and Agricultural Immunology, 10:79-87.
Apostolaki,Maria Williams,Neil A. 2004,Nasal Delivery of Antigen with the B Subunit of Escherichia coli Heat-Labile Enterotoxin Augments Antige-Specific T-Cell Clonal Expansion and Differentiation[J].Infection and Immunity, 72(7):4072-4080.
Ball JM, Hardy ME, Atmar RL, et al. 1998,Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal ,immune response in mice[J]. J Virol,72(2):1345.
Barman N N, Barman B, Sarma D K, et al. 2003,Prevalence of rotavirus, transmissible gastroenteritis virus and porcine epidemic diarrhoea virus antibodies in pigs of Assam, India[J].The Indian Journal of Animal Sciences, 73(6): 576-578.
BERMUDEZ-HUMARAN L G, LANGELLA P, MIYOSHI A, et al. 2002,Production of human papilloma virus type 16 E7 protein in Lactococcus lactis[J]. Appl Environ Microbiol, 68(2): 917-922.
BOLOTIN A, WINCKER P, MAUGER S, et al. 2001, The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. Lactis IL1403[J]. Genome Res, 11(5): 731-753.
Bouhnik Y, Flourie B, Andrieux C, Bisetti N, Briet F, Rambaud JC. 1996. Effects of Bifidobacterium sp fermented milk ingested with or without inulin on colonic bifidobacteria and enzymatic activities in healthy humans. Eur J Clin Nutr, 50(4): 269-273.
Bradney C P, Sempowski G D, Liao H X, et al. 2002,Cytocines as aduvants for the induction of anti-immunodeficiency virus peptide immunoglobulin Gand IgA antibodies in serum and mucosal secretions after nasal immunization[J].J Virol, 76(2):517-524.
Brandtzag P. 1994.Distribution and characteristics of mucosal immunoglobuilin-producing cell. In: Handbook of immunology. Boston: Academic Press, p.251-279.
Bron PA,Benchimol MG, Lambert J,Palumbo E,et al. 2002. Use of the alr gene as a food-grade selection marker in lactic acid bacteria. Appl Environ Microbiol, 68(11):5663-5670.
CARDENAS FREYTAG L ,CHENG E, MAYEUX P,et al. 1999, Effectiveness of a vaccine composed of heat-killed candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis[J]. Infect Immun, 67(2):826-833.
CHASSY B M,GIBSON E,GIUFFRIDA A. 1976, Evidence for extrachromsomal elements in Lactobacillus[J]. J Bacterial, 127(3): 1576-1578.
Cheng E, Cardenas-Freytag L, Clements JD.1999,The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin(LT)[J]. Vaccine, 18(1-2):38.
CHEUN H I, KAWAMOTO K, HIRAMATSU M, et al. 2004, Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection[J]. Appl Microbiol, 96(6):1347-1353.
Childers N K, Miller K L,Tong G, et al. 2000, Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antiger[J]. Infect Immune, 68(10):5509~5516.
Clark F,et al. 1986,Am J Dis Child, 140:350-356.
Conner M E, Zarley C D, Hu B. 1996. Virus-like particles as a rotavirus subunit vaccine. Infect Dis. 174(2) 88-92.
de RUYTER P G, KUIPERSO P, de VOSW M. 1996,Controlled gene expression systems for Lactococcus lactis with the food-grade inducer-nisin[J]. Appl Environ Microbiol, 62(10): 3662-3667.
De Simone C.,Vesely R.,Bianchi-Salvadori B.et al.1993.The role of Probiotics in modulation of the imrnune system in man and in animals.International journal of immunotherapy,9:23-28.
De VOSW M. 1999, Gene expression systems for lactic acid bacteria[J].Curr Opin Microbiol, 2(3): 289-295.
Delves BJ. 1990. Nisin and its uses as a food preserva tive. Food Technol, 44(11): 100-17.
Dewey C, Carman S, Pasma T, et al. 2003,Relationship betwee group A porcine rotavirus and management practices in swine herds in Ontario[J].The Canadian Veterinary Journal, 44(8): 649-653.
DROUAULT S, CORTHIER G, EHRLICH S.D, et al. 1999,Survival physiology, and lysis of Lactococcus lactis in the digestive tract[J]. Appl Environ Microbiol, 65: 4881-4886.
Dunn S J, Fiore L, Werner R L, et al. 1995, Imrrmnogenecity, antigenicity,and protection efficacy of baculovirus expressed VP4 trypsin cleavage products, VP5 and VP8 from rhesus rotavirus [J]. Arch. Virol, 140:1969-1978.
Eequivel F R, Lopez S, Arias C. 2000. The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response. Arch Virol. 145(4):813-825
ENOUFV, LANGELLA P, COMMISSAIRE J, et al. 2001, Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic[J]. Appl Environ Microbiol, 67 (4): 1423 -1428.
Estes M K, Cohen J. 1989. Rotavirus gene structure and function. Microbiol Rev. 53(4) 410-449.
Eva Medina, Carlos Alberto Guzman. 2001. Use of live bacterial vaccine for antigen delivery: potential and limitations. Vaccine, (19): 1573-1580.
Fujihashi K, Koga T, Van G F W, et al. 2002, A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-base adjuvants [J]. Vaccine, 20 (19-20):2431-2438.
Gil Mt, de Souza C O, Asensi M, et al. 2000, Asensi M, et al. Homotypic protection againstrotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8 subunit of the VP4 capsid protein[J]. Viral Immunol, 13(2): 187-200.
GILBERT C, ROBINSON K, Le PAGE RW, et al. 2000, Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis [ J]. Infect Immun, 68(6): 3251-3260.
Gilland S.E.,Nelson C.R. and Maxwell C.1985.Assimilation of cholesterol by Lactobacillus acidolphilus.Applied and Environmental Microbiology,49(2):377-381.
Gluck U, Gebbers JO, Gluck R. 1999,Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers[J]. J Virol, 73(9):7780.
Grangette C, Muller-Alouf H, Hols P, et al. 2004, Enhanced mucosal delivery of antigen with cell wall mutants of lactic acid bacteria[J]. Infect Immun, 72(5): 2731-2737.
Haller D.,Bode;Hummes.wp,et al.1999,Cytokine Secretin by Stimulated Monoeytes Dependson the Growth Phase and Heat Treatment of Bacteria:A comparative Study between LABtic Acid Bacteria and Invasive Pathogens[T]Microbiol Immunol, 43(10):925-935.
Harrod T, Martin M , Russell M W. 2001, Long-term persistence and recall of immune responses in aged mice after mucosal immunization [J]. Oral Microbiology and Immunology, 16(3):170-177.
Hauer AC, Breese EJ, Walker Smith JA,et al. 1997,The frequency of cells secreting interferonγ, IL-4, IL-5 and IL-10 in the blood and duodenal mucosa of childrenwith cow’s milk hypersensitivity [J]. Pediatr Res, 42(1):1-10.
Herrmann J E, Chen S C, Fynan E F. 1996. Protection against rotavirus infections by DNA vaccination. Infect Dis. 174(l) :93-97.
Hesse R A, Couture L P, Ellsworth S R. 1993, Production and characterization of VP4/VP7 reassortant swine rotaviruses derived from Gottfried and OSU parental strains[J]. Am J Vet Res 54(10): 1623-1629.
Hiroi T, YanagitaM, IijimaH,et al. 1999, Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cellinmucosa-associatedtissues[ J] . JImmunol, 162(2):821-828.
HO PO,WANG J K, LEE Y K. 2005,Intragastric administration of Lactobacillus casei expressiong transmissible gastroenteritis coronavirus spike glycoprotein induced specific antibody production [J]. Vaccine, 23: 1335-1342.
Ijaz M K, Attah-Piku S K, Redmond M J, et al. 1991, Heterotypic passive protection induced by synthetic peptides corresponding to VP7 and VP4 of bovine rotavirus[J]. J Virol, 65: 3106-3113.
Ijaz M K, Nur-E-Kamal M S A, Dar F K, et a1. 1998,Inhibition of rotavirus infection in vivo ans in vitro by a synthetic peptide from VP4[J].Vaccine, 16: 916-920.
Jin L.Z.,Ho Y.W.,Abdullah N.and Jalaludin S.1998.Growth Performance,intestinal microbial populations,and serum cholesterol of broilers fed diets containing lactobacillus cultures.Poultry Science,77:1259-1265.
Johnson M A, Misra R M, Lardelli M. 1989. Synthesis in Escherichia coli of the major glycoprotein of human rotavirus: analysis of the antigenic regions. Gene. 84(1) 73-81
Jos FML Seegers. 2002. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends in Biotechnology, (20): 508-515.
Kapikian A Z,Chanock R M. 1996. Rotaviruses. Field Virology. 3rd ed. New York, 1657-1660 Kapikian AZ,et al. 1986,11th Nobel Conference (Stockholm).Lund, Sweden:Student-litteratur, 192-214.
Kirjavainen PV, Tuomola EM,Crittenden RG, et al. 1999. In vitro adhesion and platelet aggregation properties of bacteremia-associated lactobacilli [J]. Infect Immun, 67: 2653- 2655.
Klaver F.A.M.& van der Meer R.1993.The assumed assimilation of cholesterol by lactobacilli and Bifidobacterium is due to their bile salt deconjugation activity.Environmental Microbiology,59:1120-1124.
Korpela R, Moilanen E, Saxelin M, Vapaatalo H. 1997. Lactobacillus rhamnosus GG (ATCC 53103) and platelet aggregation in vitro. Int J Food Microbiol, 37(1): 83-86.
Kovacs-Nolan J, SasakiE,Yoo D, et al. 2001, Cloning and expression of human rotavirUS spike protein, VPB, in Escherichia coli[J]. Biochem Biophys Res Commun, 282: 1183-1188.
Kushal R.,Anand S.K.&Chander H.2006.Effect of feeding miero-entrapped co-culture of Lactobacillus acidophilus and Bifidobacterium bifidum on the immune response and protection of mice infected with Salmonella typhimurium.Dairy Science and Technology,86:387-399.
Lamonica R,Kocer S,Nazarva J,et al. 2001,VP4 differentially regulates TRAF2 signaling disengaging JNK activation while directiong NF.αβto effect rotavirus-specific cellular responses [J]. J Biol Chem, 276(23):19889-19896.
LANGELLA P, Le LOIR Y. 1999, Heterologous protein secretion in Lactococcus lactis: a novel antigen delivery system [ J]. Braz J Med Biol Res, 32(2): 191-198.
LANGELLA P. 2001,Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis[ J]. Appl Microbiol Biotechnol, 67, 4119-4127.
Lee CK. 2001,Vaccination against Helicobacter pylori in non-human primate models and humans[J]. Scand J Immunol, 53(5):437.
Lee YK, Ho PS, Low CS, et al. 2004. Permanent colonization by lactobacillus casei is hindered by the low rate of cell division in mouse gut. Appl Environ Microbial, 70: 670-674.
LEEM H, ROUSSEL Y, WILK S M, et al. 2001, Expression of Helicobacter pyloriurease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice[J]. Vaccine, 19(28-29): 3927-3935.
Li TK, Fox BS. 1996, Cholera toxin B subunit binding to an antigen-presenting cell directly co-stimulates cytokine production from a T cell clone [J]. Int Immunol, 8(12):1849-1856.
Liu M, Offit P A, Estes M K. 1988. Idetification of simian rotavirus SAII genome segment 3 product. Virol. 163 :26-32
Lorenz S, Monique V, Adrian W, et al. 2002, Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle[J]. Vaccine, 20: 2913-2920.
Maassen C B M, Laman J D, Heijne den Bak-G lashouwer M J, et al. 1999, Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination ormyelin proteins for oral tolerance induction in multiple sclerosis[J]. Vaccine, 17: 2117-2128.
Maria Leonor S O liveria, Vicente Monedero, Eliane N Miyaji, et al. 2003,Expression of Streptococcus pneumoniae antigens, PsaA and PspA by Lactobacillus casei[J]. FEMS Microbiol Lett, 227:25-31.
MARIA LEONOR,OLIVEIRA S,VICENTE MONEDERO, et al. 2003, Expression of Streptococcus pneumoniae antigens,PsaA(pneumococcal surface antigen A) and PspA(pneumococcal surface protein A) by Lactobacillus casei[J]. FEMS Microbiology Letters, 227: 25-31.Mark K. H. Hoblet, L. J. Saif, E. M. Kohler. 1986,Am J Vet Res. 47∶1697-1703
Mcghee JR, Mestecky J, Dertzbaugh MT, Eldridge JK, Hirasawa M, Kiyono H. 1992. The Mucosal immune system: from fundamental concepts to vaccine development. Vaccine, 10:75-88.
McNeal M M, VanCott J L, Choi A H, et al. 2002, CD4+ T cells arethe only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G)[J]. J Virol, 76(2):560-568.
McNeal MM, Vancott JL, Choi AH, et al. 2002,CD+T cells are the onllymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with achimeric VP6 protein and the adjuvant LT(R192G)[J]. J Virol, 76(2):560.
MICHAEL THEISEN, SOE SOE, KATJA BRUNSTEDT, et al. 2004, A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies [J].Vaccine, 22(9-10): 1188-1198.
Millar DG, HirstTR, Snider DP. 2001,Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin[J]. Infect Immun, 69(5):3476-3482.
MONNE M,CHAN K W, SLOTBOOM D J, et al. 2005, Functional expression of eukaryotic membrane proteins in Lactococcus lactis[J]. Protein Sci, 14: 3048-3056.
Murphy TV, Smith PJ, Gargiullo PM, Schwartz B. 2003,The first rotavirus vaccine and intussusception:epidemiological studies and policy decisions[J].J Infect Dis, 187 (8):1309-1313.
Muscettola M,Massai L,Tanganelli C,et al. 1994,Effects of Lactobacilli on interferon Product in young and aged mice[J]. Annals New York Academy of science, 717:227-232.
NaiduA.S, Bidlack W.R.&Clemens R.A. 1999. Probiotie spectra of laetic acid bacteria(LAB). critical Reviews in Food Science and Nutrition,39:3-126.
Nakagawa I, Takahashi I, Kiyono H,et al. 1996,Oral immunization with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early TH1 and late TH2 cytokine expression in Peyer’s patches [J]. J Infect Dis, 173(6):1428-1436.
Nakamura Y, Yamamoto N, Sakai K, Okubo A, et al. 1995. Purification and characterization of angiotensin l-converting enzyme inhibitors from sour milk. J Dairy Sci, 78(4): 777-783.
Nashar TO,Webb HM,Eaglestone S,et al. 1996,Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin:receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci USA., 93(1):226-230.
Nes IF, Diep DB, Havarstein LS, Brurberg MB, Eijsink V, Holo H. 1996. Biosynthesis of bactericins in lactic acid bacteria. Antonie Van Leeuwenhoek, 70: 113-128.
NORTON P M, Le PAGE R W, WELLS JM. 1995, Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system[J]. Folia Microbiol, 40(3): 225-230.
NOUAILLE S, RIBEIRO L A, MIYOSHIA, et al. 2003, Heterologous protein production and delivery systems for Lactococcus lactis[J]. Genet Mol Res, 2(1): 102-111.
O’Sullivan M.G.,Thornton G.,O’Sullivan G.C.et al.1992.Probiotic bacteria:myth or reality.trendfood technology ,3:309-314.
Offit P A, Clark H F. 1985, Protection against rotavirus-induced gastroenteritis in a murine model by passively-acquired gastrointestinal but not circulating antibodies[J].J Virol, 54:58-64.
Ong Kong-Wee,Wilson A,Douglas Hirst,et al. 2003, The B Subunit of Escherichia coli Heat-Labile Entero toxin Enhances CD8+ Cytotoxic-T-Lymphocyte Killing of Epstein-Barr Virus-Infected Cell Lines[J]. Journal of Virology, 77(7):4298-4305.
Padilla-Noriega L, Fiore L, Rennels M B, et al. 1997,Humoral immune responses to VP4 and its cleavage products VP5 and VP8 in infants vaccinated with rhesus rotavirus[J].J Vivol, 30: 1392-1397.
Percira D.I.,Gibson G.R.2002.Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Applied and Environmental Microbiology, 68(9):4689-4693.
Perdigon G, Alvarez S, Rachid M, Aguero G, Gobbato N. 1995. Immune system stimulation by probiotics. Journal of Dariy SCI, 78: 1597-1606.
Perdigon G, Fuller R, Raya R. 2001, Lactic acid bacteria and their effect on the immune system [ J]. Curr Issues Intest Microbiol, 2(1): 27- 42.
Perdigon G,Alvarez S,Rachid M. 1995,Immune system stimulation by Probiotics[J],Journal of Dairy Science, 78:597-1606.
Perdigon G,Alvarez S. 1991,Immunoadjuvant activity of oral Lactobacillus casei:influence of dose on the secretory immune response and protective capacity in intestinal infections[J].Jounal of Dairy Reseaeh, 58(2):485-496.
Perdigon G, de Macias ME, Alvarez S,et al. 1998,Systemic augmentation of the immune response in mice by feeding fermented milk with Lactobacillus casi and Lactobacillus acidophilus[J].Immunology, 63:17-23.
Perdigon G., Medici M.,de Jorrat B.B.et al.1993.Immunomodulating effects of lactic acid bacteria on mucosal and tumoral immunity.International Journal of lmmunotherapy, 9(11):29-52.
Perdigon G., Nader de Macias M.E.,Alvarez S.et al.1990.Prevention of gastrointestinal infection using immunobiological methods with milk fermented with Lactobacillus.Journal of Dairy Research,57:255-264.
Peter H.Pouwels, Rob J.Leer, Michael Shaw, et al. 1998. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. International Journal of Food Microbiology,(41):155-167.
Pierce NS,Gowans JL. 1975,Cellular kinetics of the intestineal immune response to cholera toxoid in rats.J.Exp.Med., 142:1550-1563.
Pizza M, Giuliani M, FontanaM, et al. 2001, Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine, 19: 2534-2541.
PONTES D S, DORELLA F A, RIBEIRO L A, et al. 2003, Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7 /L12 antigen[J]. J Drug Target, 11(8-10): 489-493.
Portugal R.L.,Goncalves J.L.,Fernandes L.R.et al.2006.Effect of Lactobacillus delbrueckii on cholesterol metabolism in germfree mice and on atherogenesis in apolipoprotein E knock-out rnice.Brazilian Journal of medical and Biological Reseach,39:629-635.
Posno M,Heuvelmans PT,van Giezen MJ,et al. 1991. Complementation of the inability of Lactobacillus strains to utilize D-xylose with D-xylose catabolism-encoding genes of Lactobaci-llus pentosus. Appl Environ Microbiol, 57(9):2764-2766.
Pouwel PH, Rob J. 1996, The potential of Lactobacillus as a carrier for oral immunization: Development and preliminary characterization of vector systems for targeted delivery of antigen[ J]. Biotechnology, 44: 183-192.
Prasad BV, Wang G J, Cler JPM. 1988. Three-demessional structure of rotavirus[J]. Mol Biol. 199 269-275
Racz M L, Kroeff S S, Munford V. 2000. Molecular characterization of porcine rotaviruses from the southern region of Brazil: characterization of an atypical genotype G9 strain[J]. Clin Microbiol. 38(6) 2443-2446
RAHA A R, VARMA N R, YUSOFF K, et al. 2005, Cell surface display system for Lactococcus lactis: a novel development for oral vaccine [J]. Appl Microbiol Biotechnol, 1(6). Ramsay A J, Husband A J, Ramshaw I A,et al. 1994,The role of interleukin-6 in mucosal IgA antibody responses in vivo[J]. Science, 264(5158):561-563.
Rao C D, Gowda K, Reddy B S. 2000. Sequence analysis of vp4 and vp7 genes of nontypeable strains identifies a new pair of outer capsid proteins representing novel P and G genotypes in bovine rotaviruses [J]. Virology. 276(1) 104-113
RAVN P, ARNAU J, MADSEN S M, et al. 2000, The development of TnNuc and its use for the isolation of novel secretion signals in Lactococcus lactis[J]. Gene, 242(1-2): 347-356.
RAVN P, ARNAU J, MADSEN S M, et al. 2003, Optimization of signal peptide SP310 for heterologous protein production in Lactococcus lactis [J]. Microbiology, 149: 2193-2201.
Renner Hw, Munzner R. 1991. The possible role of probiotics as dietary antimutagen. Mutat Res. 262(4): 239-245.
Reveneau N, Geoffroy M C, Locht C, et al. 2002, Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations[J]. Vaccine, 20: 1769-1777.
Rodak L,Valicek L,et al. 2005,An ELISA optimized for porcine epidemic diarrhoea virus detection in faeces[J]. Vet Microbiol, 105(1):9-17.
ROLLWAGEN FM , PACHECO ND , CLEMENTS JD,et al. 1993,Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant[J]. Vaccine, 11(13): 1316-1320.
Roy P. 1996. Genetically engineered particularte virus-like struvtures and their use as vaccine delivery systerns. Intervirology. 39 62-64.
Salminen S.& Deighton M.1992.Lactic acid bacteria in the gut in normal and disorderedstates.Digestive Diseases,10:227-238.
Sandino A M, Jashes M, Faundex G. 1985. Role of the inner protein capsid on invitro human rotavirus transcription[J]. Gen Virol. (60),797-802.
Sereno M M, Gorziglia M I. 1994. The outer capsid protein VP4 of murine rotavirus Eb represents a new P type. Virol. (199),500-504.
Shaw DM, Gaerthe B, Leer RJ, et al. 2000. Engineering the miroflora to vaccine the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing Lactobacilli. Immunology. 100:510-518.
Shing C. Chen,David H. Jones, Ellen F. Fynan,et al . 1998,Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles [J]. J Virol, 72(7) ,5757-5761.
Stannard L M. 1977. Observation on the morPHology of two rotaviruses. Gen.Virol. (37) 435-441.
Stobie L, Gurunathan S, Prussinc,et al. 2000,The role of antigen and IL-12 in sustaining TH1 memory cells in vivo: IL-12 is required to maintain memory/effector TH1 cells sufficient to mediate protection to an infectious parasite challenge [J].Proc Natl Acad Sci USA, 97(15):8427-8432.
Takahashi H, Sasaki K, Takahashi M. 2006,Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice[J]. Vaccine, 24(17):3591-3598.
Takala M, Saris J, Tynkkynen H. 2003. Food-grade host/vector expression system for Lactobacillus casei based on complementation of Plasmid-associated phospho-beta-galactosidase gene lacG. Appl Microbiol Biotechnol, 60(5):564-570.
Taranto MP, Medici M, Perdigon G, Ruiz Holgado AP. 2000. Effect of lactobacillus reuteri on the prevention of hypercholesterolemia in mice. J Dairy Sci, 83(3): 401-403.
Thoreux K,Schmucker DL. 2001,Kefir milk enhances intestinalimmunity in young but not old rats.J Nutr, 131:807-812.
Tomohiko Ogawa, Yasuyuki Asai, Kenji Yasuda, et al. 2005,Oral immuno-adjuvantactivity of a new symbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice[J]. Nutrition Research, 25: 295-304.
Tomohiko Ogawa, Yasuyuki Asai, Kenji Yasuda, Hiromi Sakamoto. 2005.Oral immunoadjuvant activity of a new symbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice. Nutrition Research, (25): 295-304.
Truitt RL, Hanke C, Radke J,et al. 1998,Glycosphingolipids as novel targets for T-cell suppression by the B subunit of recombinant heat-labile enterotoxin [J]. Infect Immun, 66(4):1299-1308.
Tumpey TM, Renshaw M, Clements JD, et al. 2001,Mucosal delivery of inactivated influenzavaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection[J]. J Virol, 75(11):5141.
Tuomola EM, Ouwehand AC, Salminen SJ. 1999. Human ileostomy glycoproteins as a model for small intestinal mucus to investigate adhesion of probiotics [J]. Lett Appl Microbiol, 28: 159- 163.
Valenzuela S, Pizarro J, Sandino A M. 1991. PHotoaffinity labeling of rotavirus VP1 with 8-azido-ATP: identification of the viral RNA polymerase [J]. Gen Virol. 65 3964-3967. Vesikari T, et al. 1983,Lancet, 11:807-811.
Vollaard E J, Clasener H A. 1994. Colonization resistance. Antimicrob Agents Chemother, 38(3): 409-414.
Wang L, Huang J A, Nagesha H S. 1999. Bacterial expression of the major antigenic regions of porcine rotavirus VP7 induces a neutralizing immune response in mice. Vaccine. 17(20-21) 2636-2645
Ward RL. 2003,Possible mechanisms of protection elicited by candidate rotavirus vaccines as determined with the adult mouse model[J].Viral Immunol, 16(1):17-24.
WELLS JM, WILSON P W, et al. 1993, Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge[J]. Mol Microbiol, 8(6): 1155-1162.
Williams NA,Hirst TR,and Nashar TO.1999,Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.Immunology Today, 20(2):95-101.
Wu YY, Nahm MH, Guo Y, et al. 1997,Intranasal immunization of mice with PspA(pneumococcal surface protein A can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae[J]. J Infect Dis, 175:839.
WuYZ,Li JT,Mou ZR,et al. 2003.Oral immunization with rotavirus VP7 expressed intransgenic potatoes induced high titers of mucosal neutralizing IgA.Virology. 313(2):337-342.
Yamamoto M, Vancott JL, Okahashi N, et al. 1996,The role of Thl and Th2 cells for mucosal IgA responses[J]. Ann NY Acad Sci, 778:64.
Yankelevich B, Soldatenkov VA, Hodgson J,et al. 1996, Differential induction of programmed cell death in CD8+and CD4+T cells by the B subunit of cholera toxin[J]. Cell Immunol, 168(2):229-234.
Yasui H,Mike A,Ohwaki M.Immunogenicity of Bifidobacterium breve and change in antibody production in Peyer,s patches after oral administration[J].Journal of Dairy Scienee,199,72:30.
Yoo D, Lee J, Harland R, et a1. 1997, Material immunization of pregnant cattle with recombinant VP8 protein of bovine rotavirus elicits neutralizing antibodies to multiple serotypes Colostral neutralizing antibody by rotavirus VP8[J]. Adv Exp Med Biol, 412:405-411.
Zijlstra RT, Odle J, Hall WF, Petschow BW, et al. 1994 ,Effect of orally administered epidermal growth factor on intestinal recovery of neonatal pigs infected with rotavirus [J].J Pediatr Gastroenterol Nutr, 19(4):382-390.